Report: Therapeutic Proteins from Piribo.com

1. Executive Summary
2. Introduction
- 2.1 What are Therapeutic Proteins?
- 2.2 What is the Market for Therapeutic Proteins and how will it Alter in the Future?
- 2.3 Aims, Scope and Format of this Report
3. Unmet Needs and Key Issues Affecting the Therapeutic Protein Market
- 3.1 Drug Delivery Challenges
  - 3.1.1 The Majority of Therapeutic Proteins Can Only be Administered Parenterally
  - 3.1.2 Pulmonary Delivery: A Viable Alternative to Injections
    - 3.1.2.1 What is the Main Challenge in Pulmonary Delivery?
    - 3.1.2.2 Are There any Problems with Bioavailability?
    - 3.1.2.3 Does the Formulation of the Protein Affect its Delivery?
    - 3.1.2.4 Syntonix are Developing Pulmonary Technology that does not Require Deep-Lung Delivery
    - 3.1.2.5 Does Pulmonary Drug Delivery Have a Future?
  - 3.1.3 Nasal Delivery Enables Pulsed-Release Dosing, Which Aids Protein Effectiveness
    - 3.1.3.1 What Types of Nasal Drug Delivery Systems are in Development?
    - 3.1.3.2 The ChiSys(tm) Nasal Delivery System
  - 3.1.4 Oral Delivery: In Development by Altus
  - 3.1.5 Microneedles for Transdermal Delivery of Vaccines
  - 3.1.6 Are There Methods for Increasing the Half-Life of a Protein?
    - 3.1.6.1 Polymeric Delivery Ensures Proteins Remain Active for Longer
    - 3.1.6.2 Polymer-Protein Conjugation
  - 3.1.7 Can Advances in Protein Drug Delivery Result in Drugs for Treatment of CNS Disorders?
- 3.2 Manufacturing Capacity Shortfall
  - 3.2.1 Why is There a Shortfall in Manufacturing Capacity for Therapeutic Proteins?
    - 3.2.1.1 Make Vs. Buy in the 1980s
    - 3.2.1.2 CMO Manufacturing Capacity was Adequate for the Supply of Clinical Materials Only
    - 3.2.1.3 Late-Stage Products have absorbed CMO Clinical Manufacturing Capacity
  - 3.2.2 How is the Manufacturing Capacity Shortfall Being Overcome?
  - 3.2.3 Does The Future for Therapeutic Protein Manufacturing Lie with Transgenics?
- 3.3 The Cost of Therapeutic Proteins
  - 3.3.1 The Top Ten Therapeutic Proteins Each Cost at Least $10K Per Patient Per Year
  - 3.3.2 What Do the Most Costly of the Top Ten Therapeutic Proteins Have in Common?
  - 3.3.3 Yeast-Based Systems May Bring Down the Cost of Therapeutic Proteins in the Future
- 3.4 Biogeneric Competition: A Real or Limited Threat?
  - 3.4.1 How are Approval Pathways Limiting the Development of Biogenerics?
  - 3.4.2 Will the Benefits of Biogenerics be as Great as Anticipated?
  - 3.4.3 What About the High Cost of Market Entry?
  - 3.4.4 What About Manufacturing Capacity Problems?
  - 3.4.5 What Class of Therapeutic Protein is the Chief Target for Biogenerics?
  - 3.4.6 How Imminent is the Threat from Biogeneric Competition?
- 3.5 Drivers and Restraints of the Therapeutic Protein Market
4. An Overview of the Global Therapeutic Proteins Market, 2003-2004
- 4.1 The Therapeutic Proteins Market Increased by Almost 20% in 2003, Gaining Six New Products and Four Blockbusters
- 4.2 Four of the Six Newcomers are Monoclonal Antibodies
  - 4.2.1 Pegasys is the Best-Selling Newcomer to the Therapeutic Protein, and Global Pharma Market
  - 4.2.2 Humira is the Best-Selling New Monoclonal Antibody on the Market
  - 4.2.3 Fabrazyme Made $81m in Eight Months
  - 4.2.4 Amevive Was Approved for Sale in Canada in 2004
  - 4.2.5 Herceptin is Now Enjoying Success in Japan
  - 4.2.6 Xolair: Sales of $170m Expected in its First Full Year on the Market
  - 4.2.7 Newcomers will be Market Drivers in 2004 with a Triple-Digit Increase in Sales
- 4.3 The Therapeutic Protein Market Contained 11 Blockbuster Products
- 4.4 The Top Three Therapeutic Proteins Sold Over $8bn in 2003 and Held a 23% Market Share
  - 4.4.1 Procrit/Eprex - The Number One Therapeutic Protein Struggles at the Top
  - 4.4.2 Epogen is the Second Best-Selling Therapeutic Protein
  - 4.4.3 Intron A and Peg-Intron
- 4.5 Aranesp, Neulasta and Enbrel are the Most Successful Therapeutic Proteins in Terms of Growth
  - 4.5.1 Aranesp is the Fastest-Growing Therapeutic Protein
    - 4.5.1.1 Head-to-Head Studies Show Aranesp Dosed Every Two Weeks is Comparable to Epoetin Alfa Dosed Once a Week
    - 4.5.1.2 Sales of Aranesp Will Top $2.3 Billion in 2004
  - 4.5.2 Neulasta - Amgen's Neutropenia Superstar
  - 4.5.3 Enbrel Completes a Hat Trick for Amgen as the Third Fastest-Growing Therapeutic Protein on the Market
    - 4.5.3.1 Enbrel Has a Number of New Indications
    - 4.5.3.2 Side-Effects of Competitor Medications May Prove Advantageous for Enbrel
- 4.6 The Intron A Family and Genotropin were the Least Successful Therapeutic Proteins in Terms of Growth
- 4.7 The Leading Classes of Therapeutic Proteins are Erythropoietins, Monoclonal Antibodies and Interferons
  - 4.7.1 Erythropoietins Lead with a More-Than Quarter Share of the Market
  - 4.7.2 The Monoclonal Antibody Class Contained More Products than Any Other Class of Therapeutic Protein
  - 4.7.3 Interferons Sold $5.5 Billion in 2003 but are Set for Huge Losses in 2004
- 4.8 Blood Modifiers, Multiple Sclerosis and Anti-Arthritic Drugs are the Leading Therapeutic Categories for Therapeutic Proteins
  - 4.8.1 Blood Modifiers Dominate Due to Erythropoietins
  - 4.8.2 Multiple Sclerosis Drugs Hold on to Their Market Share
  - 4.8.3 Anti-Arthritic Drugs are Third Best-Selling and Fastest-Growing Therapeutic Category
- 4.9 Only Two Therapeutic Categories Saw Negative Growth in 2003
- 4.10 Amgen Dominates the Market with Almost $8 Billion in Sales
- 4.10.1 Who are Amgen?
- 4.10.2 All of Amgen's Therapeutic Proteins are Blockbusters.... And Other Facts
- 4.11 Johnson and Johnson: The Second Most-Successful Company in the Market is Losing its Grip
- 4.12 Roche are the Number Three in the Market with Drugs For a Variety of Indications
- 4.13 Wyeth: One of the Fastest-Growing Companies with all Products Experiencing Double-Digit Growth
5. The Market for Erythropoietins
- 5.1 What is Erythropoietin?
- 5.2 What are the Different Types of Erythropoietins on the Market and What are they Worth?
- 5.3 Procrit/Eprex' Sales will Recover
- 5.4 Epogen - The Class Progenitor
- 5.5 Aranesp - The New EPO on the Block
- 5.6 NeoRecormon Will Be Unaffected by Patent Expiry
- 5.7 Epogin and Espo
- 5.8 The Erythropoietin Pipeline
  - 5.8.1 Cera will Replace NeoRecormon as Roche's Leading Erythropoietin
  - 5.8.2 Dynepo is Ready to be Marketed in the EU but Still Awaits FDA Approval
  - 5.8.3 Roche Have Another Erythropoietin in Early-Stage Development
- 5.9 The Erythropoietin Class will be Worth Over $17bn by 2010
6. The Market for Monoclonal Antibodies
- 6.1 What are Monoclonal Antibodies?
- 6.2 What are the Problems Associated with Monoclonal Antibodies as Therapeutic Agents?
- 6.3 What Monoclonal Antibodies are on the Market and what are they Worth?
- 6.4 What Types of Monoclonal Antibodies are There and What Conditions do They Treat?
  - 6.4.1 Murine
  - 6.4.2 Chimeric Antibodies
  - 6.4.3 Humanised Antibodies (CDR-Grafted)
  - 6.4.4 Human Antibodies
  - 6.4.5 Receptor-Antibody Fusion Protein
  - 6.4.6 Chimeric Monoclonal Antibodies Dominate the Market
  - 6.4.7 Monoclonal Antibodies Have Eight Main Indications, of Which Arthritis is the Best Selling
  - 6.4.8 Why do Arthritis Medications Dominate?
  - 6.4.9 Non-Hodgkin's Lymphoma Drugs Come a Close Second to Arthritis Medications
  - 6.4.10 What is Non-Hodgkin's Lymphoma and how Prevalent is it?
- 6.5 Remicade is the Best-Selling Monoclonal Antibody
  - 6.5.1 How Safe is Remicade?
  - 6.5.2 Remicade Lacks Patent Protection and Market Exclusivity but Continues to Grow
- 6.6 Genentech's Rituxan Leads the Way in Treatment for Non-Hodgkin's Lymphoma
- 6.7 Herceptin is the Third Best Selling MAb on the Market
- 6.8 What are the Most Promising New MAbs on the Market?
  - 6.8.1 Abbott's Humira is the First in its Class
  - 6.8.2 Bexxar and Zevalin Represent Another New Class of MAbs
  - 6.8.3 Avastin: An Important New Treatment for the Third Most Fatal Cancer in the US
  - 6.8.4 Erbitux will Enjoy Success, but not on the Same Scale as Avastin
- 6.9 The Monoclonal Antibody Late-Stage Pipeline
  - 6.9.1 Tysabri Could Take a 50% Share of the Multiple Sclerosis Market
- 6.10 The Monoclonal Antibody Early-Stage Pipeline
- 6.11 Monoclonal Antibodies Will be Worth Over $26 Billion by 2010
7. The Market for Interferons
- 7.1 What is an Interferon?
- 7.2 What Diseases do Interferons Treat?
- 7.3 What Interferons are on the Top 400 Market and How Much are they Worth?
- 7.4 The Intron A Family versus Pegasys: Pegasys Looks Set for Victory
  - 7.4.1 What is Pegasys and what makes it Different from Other Hepatitis Treatments?
  - 7.4.2 Pegasys Can Now Also Treat Hepatitis B
  - 7.4.3 Pegasys will be the Market Leader by 2005
- 7.5 Who Will Win the War to Become the Top-Selling Multiple Sclerosis Treatment?
  - 7.5.1 Market-Leading Avonex will soon Succumb to Competitive Pressure from Rebif
  - 7.5.2 Betaseron will Remain a Best-Seller, But Growth will be Relatively Flat
- 7.6 The Interferon Pipeline
  - 7.6.1 Nastech Pharma Have a Nasal Interferon Available for Licensing
- 7.1 Box Who are Nastech Pharmaceuticals?
  - 7.6.2 Amarillo Biosciences are Developing an Oral Interferon for Hepatitis C
- 7.2 Box Who are Amarillo Biosciences?
- 7.7 The Market for Interferons will be Worth over $12bn in 2010
8. The Market for Insulin
- 8.1 What is Insulin?
- 8.2 How Prevalent is Diabetes?
- 8.3 What Insulin Treatments are on the Market and What are They Worth?
- 8.4 Humulin Will Lose its Spot at the Top to Lilly's New and Improved Humalog
- 8.5 Sanofi-Aventis' Lantus is Rising Fast to the Top of the Insulin Market
- 8.6 Recently-Approved Insulins: How Will They Perform?
  - 8.6.1 Novo Nordisk Claims New Product Superior to Lantus
  - 8.6.2 Apidra May Benefit from Lantus' Success
- 8.7 The Insulin Pipeline
  - 8.7.1 Exubera will be the First Non-Injected Insulin on the Market
  - 8.7.2 Novo Nordisk May Launch Their Inhaled Insulin by 2009
  - 8.7.3 Generex Biotech Lead the Race to Market the First Oral Insulin
  - 8.7.4 Will HIM2 be the First Insulin Pill on the Market?
- 8.8 Lantus will be the Top Selling Insulin in 2010, when the Market will be Worth $9.5bn
9. The Market for Colony Stimulating Factor
- 9.1 What is Colony Stimulating Factor and What Diseases does it Treat?
- 9.2 What CSFs are Available and What is the Market Worth?
- 9.3 Neupogen: Amgen's Orphan Drug for the Treatment of Neutropenia
- 9.4 Amgen Has Released a New-Improved Form of Neupogen: Neulasta
- 9.5 Little Competition for Amgen in the Neutropenia Market
- 9.6 The CSF Pipeline
- 9.7 The CSF Market will be Worth Over $4.8bn by 2010
10. The Market for Other Classes of Therapeutic Protein
- 10.1 The Market for Blood Factors
  - 10.1.1 What are Blood Factors and which ones Feature on the Therapeutic Protein Market?
  - 10.1.2 What is Haemophilia and how Prevalent is it?
  - 10.1.3 NovoSeven is the Top Selling Haemophilia Drug, but not for Long
  - 10.1.4 Kogenate: The Runner-Up to NovoSeven
  - 10.1.5 Benefix: Wyeth's Breakthrough Haemophilia B Treatment
  - 10.1.6 ReFacto: Wyeth's Breakthrough Haemophilia A Treatment
  - 10.1.7 The Blood Factor Pipeline
  - 10.1.8 By 2010 Blood Factors will be Worth in Excess of $2.5bn
- 10.2 The Market for Therapeutic Vaccines
  - 10.2.1 The Market for Therapeutic Vaccines is Sparse
  - 10.2.2 Why is the Market Experiencing Flat Growth?
  - 10.2.3 The Therapeutic Vaccine Pipeline
  - 10.2.4 Sales of Therapeutic Vaccines will Grow in Double-Digits in the Forecast Period
- 10.3 The Market for Growth Hormones
  - 10.3.1 What is Growth Hormone and What is the Market Worth?
  - 10.3.2 What is Growth Failure and What Causes it?
  - 10.3.3 Genotropin: Pfizer Under Investigation
  - 10.3.4 Humatrope: Eli Lilly's Growth Hormone
  - 10.3.5 Nutropin, Nutropin Depot and Protropin
  - 10.3.6 The Hormone Market will Experience Flat Growth Between 2004 and 2010
- 10.4 The Market for Enzymes
  - 10.4.1 What are Enzymes, what Diseases do they Treat and what is the Market Worth?
  - 10.4.2 What is in the Enzyme Pipeline?
  - 10.4.3 All Enzymes on the Market will Enjoy Positive Growth Between 2004 and 2010
- 10.5 The Market for Enbrel
  - 10.5.1 What is Enbrel and what is it Worth?
  - 10.5.2 Who are Enbrel's Competitors on the Therapeutic Protein Market?
  - 10.5.3 Enbrel will Grow with a CAGR of Almost 16% Between 2004 and 2010
- 10.6 The Market for Copaxone
  - 10.6.1 What is Copaxone and What is it Worth?
  - 10.6.2 New Indications for Copaxone are in the Pipeline
  - 10.6.3 Who are Copaxone's Competitors on the Therapeutic Protein Market?
  - 10.6.4 Sanofi-Aventis Will Overtake Teva in Sales of Copaxone
11. Forecast Summary for Therapeutic Proteins, to 2010
- 11.1 Aranesp Will be the Market Leader in 2010
- 11.2 The Market Leader Will Hold A Smaller Market Share in 2010 than in 2003
- 11.3 Monoclonal Antibodies will Become the Leading Class of Therapeutic Protein
- 11.4 Monoclonal Antibodies and Insulin will be the Fastest Growing Classes
- 11.5 Blood Modifiers will Remain the Top Therapeutic Category
- 11.6 Amgen will Remain the Market Leaders and Retain Their Market Share
- 11.7 The Therapeutic Protein Market will Total Over $90bn by 2010
12. Conclusion: The Market will Continue its Double-Digit Growth for the Foreseeable Future
Graphs
- Graph 1.1 The Top 20 Therapeutic Proteins by Revenue ($m), 2003
- Graph 3.1 Cost of Per Patient ($m) of the Top Ten Therapeutic Proteins, 2003
- Graph 4.1 Revenues ($m) for Newcomers to the Therapeutic Protein Market, 2003-2004
- Graph 4.2 Revenues ($m) for New Blockbusters on the Market, 2003
- Graph 4.3 Revenues ($m) for Blockbuster Therapeutic Proteins, 2003
- Graph 4.4 Global Procrit/Eprex Sales ($m), 2001-2004
- Graph 4.5 Global Epogen Sales ($m), 2001-2004
- Graph 4.6 Global Intron A Family Sales ($m), 2001-2004
- Graph 4.7 Top Ten Winners and Losers in the Global Therapeutic Protein Market by Growth Rate (%), 2003
- Graph 4.8 Global Aranesp Sales ($m), 2001-2004
- Graph 4.9 Global Neulasta Sales ($m), 2002-2004
- Graph 4.10 Global Enbrel Sales ($m), 2001-2004
- Graph 4.11 Global Sales ($m) of Therapeutic Proteins by Class, 2003
- Graph 4.12 Class Winners and Losers in the Therapeutic Protein Market by Growth Rate (%), 2003
- Graph 4.13 Copaxone Sales ($m) by Company, 2001-2004
- Graph 4.14 Market Shares (%) for Anti-Arthritic Therapeutic Proteins, 2003-2004
- Graph 4.15 Winners and Losers in the Therapeutic Protein Market by Growth Rate (%), according to Therapeutic Category, 2003
- Graph 4.16 Top Ten Companies in the Therapeutic Protein Market by Revenue ($m), 2003
- Graph 4.17 Amgen's Annual R&D Expenditure ($m), 1993-2003
- Graph 4.18 Company Winners and Losers in the Therapeutic Protein Market by Growth Rate (%), 2003
- Graph 5.1 Forecast of Global Procrit/Eprex Sales ($m), 2004-2010
- Graph 5.2 Forecast of Global Epogen Sales ($m), 2004-2010
- Graph 5.3 Forecast of Global Aranesp Sales ($m), 2004-2010
- Graph 5.4 Forecast of Global NeoRecormon Sales ($m), 2004-2010
- Graph 5.5 Forecast of Global Epogin Sales ($m), 2004-2010
- Graph 5.6 Forecast of Global Espo Sales ($m), 2004-2010
- Graph 5.7 The Global Market ($m) for Erythropoietins, 2004 Versus 2010
- Graph 5.8 The Global Market ($m) for Erythropoietins, 2010
- Graph 5.9 CAGR (%) for the Global Erythropoietins Market, 2004-2010
- Graph 5.10 Forecast for the Global Erythropoietins Market ($m), 2004-2010
- Graph 6.1 Global Revenues ($m) for MAbs by Class, 2003
- Graph 6.2 Global Revenues ($m) for MAbs by Indication, 2003
- Graph 6.3 Global Sales ($m) of Remicade by Company, 2004-2010
- Graph 6.4 Global Rituxan Sales ($m), 2004-2010
- Graph 6.5 Global Herceptin Sales ($m) by Company, 2004-2010
- Graph 6.6 Global Humira Sales ($m), 2004-2010
- Graph 6.7 Global Zevalin Sales ($m), 2004-2010
- Graph 6.8 Global Bexxar Sales ($m), 2004-2010
- Graph 6.9 Global Avastin Sales ($m), 2004-2010
- Graph 6.10 Global Erbitux Sales ($m), 2004-2010
- Graph 6.11 Global Sales ($m) of Selected Monoclonal Antibodies, 2010
- Graph 6.12 CAGRs (%) for Selected Monoclonal Antibodies, 2004-2010
- Graph 6.13 Total Global Revenue ($bn) for the MAb Market, 2004-2010
- Graph 7.1 Global Sales ($m) of the Intron A Family Versus Pegasys, 2004-2010
- Graph 7.2 Global Intron A Family Sales ($m), 2004-2010
- Graph 7.3 Global Sales ($m) of Interferons for Multiple Sclerosis, 2004-2010
- Graph 7.4 Best-Selling Interferons ($m), 2010
- Graph 7.5 CAGRs (%) for the Best-Selling Interferons, 2004-2010
- Graph 7.6 Total Global Revenues ($bn) for the Interferon Market, 2004-2010
- Graph 8.1 Global Humulin and Humalog Sales ($m), 2004-2010
- Graph 8.2 Global Lantus Sales ($m), 2004-2010
- Graph 8.3 Global Levemir Sales ($m), 2004-2010
- Graph 8.4 Global Apidra Sales ($m), 2004-2010
- Graph 8.5 Global Exubera Sales ($m), 2005-2010
- Graph 8.6 Global Insulin Sales ($m), 2010
- Graph 8.7 CAGRs (%) for Insulins, 2004-2010
- Graph 8.8 Total Global Revenues for the Insulin Market ($m), 2004-2010
- Graph 9.1 The Global CSF Market ($m), 2004-2010
- Graph 10.1 Global Revenues ($m) for Blood Factor Brands 2004 Versus 2010
- Graph 10.2 The Global Blood Factor Market ($m), 2004 Versus 2010
- Graph 10.3 Global Revenue ($m) for Therapeutic Vaccines, 2004 and 2010
- Graph 10.4 Global Revenue ($m) for Growth Hormones, 2004 Versus 2010
- Graph 10.5 The Global Enzyme Market ($m), 2004 vs. 2010
- Graph 10.6 Global Enbrel Revenue ($m) by Company, 2004 vs. 2010
- Graph 10.7 Global Sales ($m) for Copaxone Versus Competitor Therapeutic Proteins for MS, 2004-2010
- Graph 11.1 Top Ten Therapeutic Proteins Globally by Revenue ($m), 2010
- Graph 11.2 Revenue ($m) for Therapeutic Proteins by Class, 2010
- Graph 11.3 CAGRs (%) for Classes of Therapeutic Protein, 2003-2010
- Graph 11.4 Global Revenues ($m) for Therapeutic Proteins by Therapeutic Category, 2010
- Graph 11.5 Top Ten Companies by Revenue ($m) in the Therapeutic Protein Market, 2010
- Graph 12.1 Total Revenue ($m) for the Therapeutic Protein Market, 2003-2010
Tables
- Table 1.1 Top 3 Classes, Therapeutic Categories and Indications for Therapeutic Proteins by Revenue, 2003
- Table 2.1 Examples of Diseases that Therapeutic Proteins Treat
- Table 3.1 Methods of Administration (MoA) for the Top Ten Therapeutic Proteins (2003)
- Table 3.2 Features of the Top Ten Therapeutic Proteins (2003), Relevant to Cost
- Table 3.3 Barriers to Overcome and Entry Strategies to Compete Successfully in the Biogenerics Market
- Table 3.4 Manufacturing: Make or Buy?
- Table 3.5 Drivers and Restraints of the Therapeutic Protein Market, 2005
- Table 4.1 The Global Therapeutic Protein Market ($m), 2002-2003
- Table 4.2 Top 20 Therapeutic Proteins by Revenue ($m), 2003
- Table 4.3 Newcomers to the Global Therapeutic Protein Market, 2003
- Table 4.4 Revenues ($m) for Blockbuster Therapeutic Proteins, 2003
- Table 4.5 Revenue ($m) for Arthritis Medications in the Top 100, 2003
- Table 4.6 Revenue ($m) for Classes of Therapeutic Protein, 2003
- Table 4.7 Top Therapeutic Categories for Therapeutic Proteins by Revenue ($m), 2003
- Table 4.8 Blood Modifying Therapeutic Proteins by Class and Revenue ($m), 2003
- Table 4.9 Global Revenues ($m) for Multiple Sclerosis Therapeutic Proteins, 2003
- Table 4.10 Global Revenues ($m) for Anti-Arthritic Therapeutic Proteins, 2003
- Table 4.11 Revenues and Market Shares (%) for Anti-Arthritic Therapeutic Proteins, 2003-2004
- Table 4.12 Revenues ($m) for Hormonal Treatments on the Therapeutic Proteins Market, 2003
- Table 4.13 Amgen's Therapeutic Proteins by Global Revenues ($m), 2003
- Table 4.14 Roche's Therapeutic Proteins by Global Revenues ($m), 2003
- Table 4.15 Wyeth's Therapeutic Proteins by Global Revenues ($m), 2003
- Table 5.1 Global Erythropoietin Revenue ($m), 2003
- Table 5.2 The Erythropoietin Pipeline, 2005
- Table 5.3 The Global Market ($m) for Erythropoietins, 2004-2010
- Table 6.1 The Global MAb Market ($m), 2003
- Table 6.2 Classes and Indications of MAbs on the Market, 2003
- Table 6.3 Selected MAbs in Late-Stage Development, 2005
- Table 6.4 Selected MAbs in Early-Stage Development, 2005
- Table 6.5 Global Sales ($m) of Monoclonal Antibodies, 2004-2010
- Table 7.1 Indications of Currently Marketed Interferons, 2005
- Table 7.2 The Global Interferon Market ($m), 2003
- Table 7.3 The Interferon Pipeline, 2005
- Table 7.4 Global Interferon Revenues ($m), 2004-2010
- Table 8.1 Insulin Treatments on the Top 400 Market, 2003
- Table 8.2 Selected Products in the Insulin Pipeline, 2005
- Table 8.3 Total Global Insulin Sales ($m), 2004-2010
- Table 9.1 The Global CSF Market ($m), 2003
- Table 9.2 The CSF Pipeline, 2005
- Table 9.3 Value of the Global CSF Market ($m), 2004-2010
- Table 10.1 The Global Blood Factors Market ($m), 2003
- Table 10.2 The Blood Factor Pipeline, 2005
- Table 10.3 Global Revenues ($m) for the Top-Selling Blood Factors, 2004 and 2010
- Table 10.4 The Therapeutic Vaccine Pipeline, 2005
- Table 10.5 Global Revenues ($m) for Therapeutic Vaccines 2004 Versus 2010
- Table 10.6 The Global Market ($m) for Growth Hormones, 2003
- Table 10.7 The Growth Hormone Pipeline, 2005
- Table 10.8 Global Revenues ($m) for Growth Hormones, 2004 Versus 2010
- Table 10.9 The Global Enzyme Market ($m), 2003
- Table 10.10 The Enzyme Pipeline, 2005
- Table 10.11 Global Revenue ($m) for Enzymes, 2004 vs. 2010
- Table 10.12 Positions for Anti-Arthritic Therapeutic Proteins, 2003 and 2009
- Table 10.13 Global Copaxone Sales ($m), 2004-2010
- Table 11.1 Top Ten Therapeutic Proteins Globally by Revenue ($m), Including Co- Marketing Splits, 2010
- Table 11.2 Top Ten Therapeutic Proteins Globally by Revenue ($m), Excluding Co-Marketing Splits, 2010
- Table 11.3 Revenue ($m) for Therapeutic Proteins by Class, 2010
- Table 11.4 CAGRs (%) for Classes of Therapeutic Protein, 2003-2010
- Table 11.5 Global Revenues ($m) for Therapeutic Proteins by Therapeutic Category, 2010
- Table 11.6 Top Ten Companies in the Therapeutic Protein Market Globally by Revenue ($m), 2010
- Table 11.7 The Global Therapeutic Proteins Market ($m), 2010
- Table 12.1 Therapeutic Proteins in the Pipeline with Non-Parenteral Methods of Delivery, 2005
Figures
- Figure 4.1 The Market Share (%) for All Blockbuster Therapeutic Proteins, 2003
- Figure 4.2 Global Market Shares (%) for the Top-Selling Therapeutic Proteins, 2003
- Figure 4.3 Global Market Shares (%) for Therapeutic Proteins by Class, 2003
- Figure 4.4 Market Shares (%) in the Global Therapeutic Protein Market by Company, 2003
- Figure 5.1 The Erythropoietin Feedback Loop
- Figure 6.1 Protocol for the Production of Monoclonal Antibodies (Anti-Snake Venom)
- Figure 6.2 Global Market Shares (%) for MAb Classes, 2003
- Figure 6.3 Global Market Shares (%) for MAbs by Indication, 2003
- Figure 11.1 Global Market Shares (%) for the Top Ten Therapeutic Proteins, 2010
- Figure 11.2 Global Market Shares (%) for Classes of Therapeutic Protein, 2010
- Figure 11.3 Global Market Shares (%) for Categories of Therapeutic Protein, 2010
- Figure 11.4 Global Market Shares (%) for the Top Ten Companies in the Therapeutic Protein Market, 2010

Therapeutic

Therapeutic Proteins

Price £1,999.00

Summary

WHY YOU MUST BUY THIS REPORT

COMPANIES MENTIONED IN THIS REPORT

Content

Bookmark this Product